abstract |
The present invention relates to the treatment of cancer, such as prostate cancer (eg castration-resistant prostate cancer (CRPC)). More specifically, the present invention relates to the treatment of human patients with prostate cancer (eg CRPC, eg metastatic CRPC) by combination therapy comprising PD-1 axis binding antagonist and antiandrogen. . |